人胚胎干细胞衍生多巴胺能神经元治疗帕金森病的临床试验：新时代的曙光。
Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.
机构信息
Department of Clinical Neuroscience and Cambridge Stem Cell Institute, Forvie Site, Cambridge CB2 0PY, UK.
Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, and Lund Stem Cell Centre, Department of Experimental Medical Science, Lund University, 22184, Lund, Sweden.
出版信息
Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.
Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.
基于干细胞的帕金森病治疗方法正在进入一个崭新而令人兴奋的时代，有几个研究小组正在开展多能干细胞（PSC）衍生的多巴胺神经元的临床试验。由于许多研究小组正在进行或已经完成了符合 GMP 标准的细胞制造，我们从最近的第四次 GForce-PD 会议中重点强调了一些关键的临床转化考虑因素。
Zotero 插件